Aripiprazole Tablet
Product Images NDC 68788-8089

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68788-8089). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A line graph comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Two lines, a solid blue line for Aripiprazole and a dashed red line for placebo, plot relapse proportions over time, with Aripiprazole showing a lower relapse proportion.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A Kaplan-Meier survival curve chart comparing the proportion of subjects with relapse over 364 days from randomization between Aripiprazole and placebo groups. The graph depicts relapse rates on the vertical axis and days from randomization on the horizontal axis, with subject counts at risk listed below for each group over time.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart illustrating the fold change and 90% confidence interval for Dehydro-Aripiprazole levels, comparing area under the curve (AUC) and maximum concentration (Cmax) with various CYP3A4 and CYP2D6 inhibitors and other drugs. The x-axis shows change relative to a reference without interacting drugs, ranging from 0.5 to 3.0.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A forest plot depicting fold change and 90% confidence intervals for pharmacokinetic parameters (DMVDRP, AUC, Cmax, INR) of various drugs including dextromethorphan, warfarin (S- and R- enantiomers), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. It shows changes relative to a reference without interacting drug on a scale from 0.5 to 3.0.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' displaying fold change and confidence intervals for various factors including CYP2D6 metabolism status, gender, age, hepatic impairment, and severe renal impairment. The horizontal axis shows change relative to reference with values from 0.5 to 3.0. Data points with error bars illustrate AUC and Cmax changes for each factor.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A forest plot titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the effect of various factors like CYP2D6 metabolizer status, gender, age, hepatic impairment, and severe renal impairment on the pharmacokinetics (AUC and Cmax) of dehydro-aripiprazole. Data points with confidence intervals depict fold changes relative to reference values on a horizontal axis ranging approximately from 0.5 to 3.0.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart illustrating the fold change and 90% confidence intervals for Aripiprazole's AUC and Cmax when administered with various CYP3A4 inhibitors, CYP2D6 inhibitors, inducers, gastric acid blockers, and other drugs. The x-axis shows change relative to reference without interacting drug, ranging from 0.0 to 3.0.*

FDA Label Image

Aripiprazole Tablets Usp 5mg (Aripiprazole Fig2 New)

Label for Aripiprazole Tablets USP 5 mg, a prescription oral tablet by Preferred Pharmaceuticals Inc. The label notes the generic equivalence to Abilify, packaging and manufacturing details, and storage instructions. Directions for use are printed in English and Spanish, emphasizing use as directed by a doctor, with blank spaces for dosage and timing instructions.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure of Aripiprazole, a human prescription drug active ingredient in tablet form at 5 mg strength. The diagram shows the molecular arrangement, including chlorine atoms, nitrogen atoms, and a characteristic multi-ring structure.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier curve chart showing the proportion of subjects with relapse over days from randomization. The chart compares two groups: one treated with aripiprazole (solid blue line) and a placebo group (dashed red line). Beneath the graph, a table displays the number of subjects at risk at various time points for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.